CIAM
CADL icon

Caitong International Asset Management’s Candel Therapeutics CADL Stock Holding History

Caitong International Asset Management’s Portfolio CADL Stock Details CADL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$828 Buy
169
+168
+16,800% +$914 ﹤0.01% 1493
2025
Q4 		$6 Buy
+1
New +$5 ﹤0.01% 1814
2025
Q3 		– Sell
-2,261
Closed -$11.4K – 1995
2025
Q2 		$11.4K Buy
2,261
+1,890
+509% +$9.73K 0.01% 669
2025
Q1 		$2.1K Buy
371
+40
+12% +$327 ﹤0.01% 1315
2024
Q4 		$2.87K Buy
+331
New +$1.96K ﹤0.01% 1121

Other funds holding CADL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Caitong International Asset Management's CADL Position: Q1 2026 in Review

Caitong International Asset Management increased its Candel Therapeutics (CADL) stake by 16,800% in Q1 2026, buying an estimated $914 and bringing the position to 169 shares worth $828. The position accounts for ﹤0.01% of the portfolio, ranked #1493.

Caitong International Asset Management first reported a position in CADL in Q4 2024 and has held it in 5 quarters since. The position peaked at $11.4K in Q2 2025. 114 funds tracked by Wall St. Rank hold CADL as of Q1 2026.

  • Caitong International Asset Management held 169 shares of Candel Therapeutics worth $828 as of Q1 2026.
  • Caitong International Asset Management bought 168 Candel Therapeutics shares in Q1 2026, an estimated $914.
  • Candel Therapeutics made up ﹤0.01% of Caitong International Asset Management's portfolio in Q1 2026, its #1493 holding.
  • Caitong International Asset Management first reported a position in Candel Therapeutics in Q4 2024 and has held it in 5 quarters since.
  • Caitong International Asset Management's Candel Therapeutics position peaked at $11.4K in Q2 2025.
  • 114 funds tracked by Wall St. Rank held Candel Therapeutics as of Q1 2026.

Based on Caitong International Asset Management's 13F filing for Q1 2026, filed 11 May 2026.